Company Drug

Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis

By Fineline Cube #Market launch
Boehringer Ingelheim's Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim announced the first prescription issuance for Jascayd (nerandomilast tablets) in Shanghai, marking the commercial launch of the world’s first approved selective PDE4B inhibitor for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug, which received China marketing authorization in October 2025, offers multifaceted anti-fibrotic, vascular protective, and immunomodulatory effects with a favorable safety profile designed to address the high discontinuation rates associated with existing therapies.

Commercial Launch Milestone

ElementDetail
ProductJascayd (nerandomilast tablets)
Generic NameNerandomilast
Drug ClassSelective phosphodiesterase 4B (PDE4B) inhibitor – first-in-class globally
IndicationsIdiopathic pulmonary fibrosis (IPF); progressive pulmonary fibrosis (PPF)
MechanismAnti-fibrotic activity + vascular protection + immunomodulation
DeveloperBoehringer Ingelheim
China ApprovalOctober 2025
First PrescriptionMarch 6, 2026 (Shanghai)
Key DifferentiationImproved tolerability vs. existing IPF therapies (nintedanib, pirfenidone)

Clinical Profile & Unmet Need

ParameterJascayd (Nerandomilast)Existing Therapies (Nintedanib/Pirfenidone)Clinical Advantage
EfficacySignificantly slows lung function decline (FVC)Modest FVC decline reductionComparable efficacy
Safety/TolerabilityFavorable profileHigh discontinuation rates due to GI toxicity (nintedanib) / photosensitivity (pirfenidone)Reduced treatment discontinuation
MechanismSelective PDE4B inhibition (anti-fibrotic + immunomodulatory)Multi-kinase inhibition (nintedanib) / unclear (pirfenidone)Targeted mechanism; potentially better tolerability
Patient ComplianceExpected improvement~30-40% discontinuation within 12 monthsAddresses critical unmet need

Market Context & Strategic Value

FactorImplication
IPF/PPF BurdenChina: 500,000+ IPF patients; rising diagnosis rates with improved HRCT access; median survival 3-5 years without treatment
Existing Therapy LimitationsNintedanib and pirfenidone slow decline but poorly tolerated; ~50% of patients discontinue or refuse initiation
Jascayd PositioningFirst-line option for treatment-naïve patients; switch option for intolerant patients; potential for combination
Boehringer PortfolioComplements Ofev (nintedanib) with differentiated mechanism; addresses portfolio gap in tolerability-driven market
Global ExpansionChina-first approval strategy; U.S./EU filing anticipated 2026-2027 based on China data package

Competitive Landscape

ProductDeveloperMechanismChina StatusJascayd Differentiation
Ofev (nintedanib)Boehringer IngelheimMulti-kinase inhibitor (VEGFR, FGFR, PDGFR)Approved (IPF, PPF)Same company; nerandomilast offers improved tolerability alternative
Esbriet (pirfenidone)RocheAnti-fibrotic (mechanism unclear)Approved (IPF)Selective PDE4B mechanism vs. unclear MOA; better safety profile
Jascayd (nerandomilast)Boehringer IngelheimSelective PDE4B inhibitorLaunched (March 2026)First-in-class; tolerability advantage; multifaceted mechanism

Launch Execution & Forward Outlook

  • 2026 Rollout: Tier-1 city expansion (Beijing, Guangzhou, Shenzhen); tertiary hospital pulmonology center penetration
  • NRDL Negotiation: 2026-2027 national reimbursement list inclusion critical for volume access
  • Physician Education: Differentiation from nintedanib tolerability profile; PDE4B mechanism education
  • Patient Support: Adherence programs addressing prior therapy discontinuation patterns
  • Global Strategy: U.S. FDA Breakthrough Therapy designation potential; EU EMA accelerated assessment

Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch performance, global regulatory expansion, and competitive positioning for nerandomilast in pulmonary fibrosis. Actual results may differ due to reimbursement negotiations, physician adoption patterns, and competitive dynamics with established anti-fibrotic therapies.-Fineline Info & Tech

Related Post

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Fineline Cube
Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Fineline Cube
Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

Fineline Cube

You Missed

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion